News & Articles

Non-exclusive OEM license grants worldwide rights for Optimer binder in molecular biology applications

Third consecutive project demonstrates performance advantages of synthetic binders in therapeutic development applications

In this guest editorial, Dr. Katherine Bridge, University of York, explains how aptamers could unlock new opportunities for more targeted and effective cancer treatments

Development agreement applies Optimer binders to cancer imaging and therapeutics

Neuro-Bio is creating a first-of-its-kind diagnostic, targeting a novel biomarker in Alzheimer’s Disease

Accelerated platform delivers validated biomarkers with ready-to-use Optimer ligands in months rather than years

Licensing with a global enzyme provider for two Optimer reagents in research and diagnostics

New data show Optimer delivery vehicle could be used in precision medicines across diverse fibrotic diseases

New test format enhances commercialisation potential

Successful project delivery of Optimer binders with proven function as vaccine adjuvants

New collaboration will evaluate Aptamer’s fibrotic liver delivery vehicles with siRNA

Optimer binders will be developed for use in a cervical cancer blood test

The goal is the development of a lateral flow test for early disease detection